✦ LIBER ✦

Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma

✍ Scribed by Osnat Bairey; Dorit Blickstein; Yehudit Monselise; Judith Lahav; Pinhas Stark; Miron Prokocimer; Hila Magen Nativ; Ilia Kirgner; Idit Pazgal; Mati Shaklai

Book ID: 114793996
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 156 KB
Volume: 76
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2005.00620.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early-mid treatment C-reactive protein l

Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin’s lymphoma

✍ Yair Herishanu; Chava Perry; Rony Braunstein; Ur Metser; Odelia Goor; Ori Rogows 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 465 KB

Non-melanoma skin cancer may be a marker

Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma

✍ Henrik Hjalgrim; Morten Frisch; Hans H. Storm; Bengt Glimelius; Jakob Bøje Peder 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB 👁 2 views

According to recent results, patients with non-melanoma skin cancers are at increased risk of developing non-Hodgkin's lymphoma (NHL). The prognostic significance of this association is unknown. Two cohorts of patients with a first diagnosis of non-melanoma skin cancer and a subsequent diagnosis of

High titres of IgM-antiphospholipid anti

High titres of IgM-antiphospholipid antibodies are unrelated to pathogenicity in patients with non-Hodgkin’s lymphoma

✍ W. Miesbach; I. Scharrer; R. A. Asherson 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 63 KB

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa

A prospective study of intensive inducti

A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin’s lymphoma and two or three adverse prognostic factors

✍ Dumontet, C; Thieblemont, C; Espinouse, D; Bouafia, F; Hequet, O; Salles, G; Coi 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 110 KB

Codeletion of CDKN2 and MTAP genes in a

Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma

✍ Martin H. Dreyling; Diane Roulston; Stefan K. Bohlander; James Vardiman; Olufunm 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Identifying the various genetic alterations that contribute to lymphomagenesis is key to our improved understanding of the biological behavior of the disease. Recently, we and others have defined a tumor suppressor region on the short arm of chromosome 9 harboring a cluster of genes, including MTAP,